Our Transactions

 

Transformative transactions and engagements

Locust Walk has a robust record of success in closing high-value transactions for multiple clients. Our work spans the spectrum of therapeutic areas and modalities, from cutting edge gene therapies in oncology to over-the-counter consumer pharmaceutical products. A selection of our engagements appears below. Please click on each case study or news release for greater detail about each transformative transaction. Contact us if you would like to learn more.

CLIENT: TWiB

TRANSACTION: Japan collaboration for a phase 2 orphan dermatology asset

VIEW CASE STUDY >>

CLIENT: Regenacy Pharmaceuticals

TRANSACTION: Advised on Chinese join venture and license with 3E Bioventures

VIEW CASE STUDY >>

CLIENT: Nevakar

TRANSACTION:  Licensing agreement for NVK-002 with Zhaoke Ophthalmology in Greater China, South Korea and the Southeast Asian territories

VIEW CASE STUDY >>

CLIENT: C4 Therapeutics

TRANSACTION: IPO Advisory assignment helping raise $210M in a NASDAQ IPO

VIEW CASE STUDY >>

CLIENT: C4 Therapeutics

TRANSACTION: Rapid financing process led to oversubscribed crossover financing

VIEW CASE STUDY >>

CLIENT: Inspirion Delivery Sciences

TRANSACTION: Asset sale as part of court-ordered dissolution process

 

CLIENT: Esteve

PARTNER: Leitat

TRANSACTION: Esteve and Leitat announce strategic partnership to collaborate in research and development

VIEW PRESS RELEASE >>

CLIENT: Regenacy Pharmaceuticals

TRANSACTION: $30M Series A Financing

VIEW CASE STUDY >>

CLIENT: BioPharmX

PARTNER: Timber Pharmaceuticals

TRANSACTION: Sell-side engagement leading to a reverse merger 

VIEW CASE STUDY >>

CLIENT: Targovax

PARTNER: IOVaxis Therapeutics

TRANSACTION: Sell-side engagement leading to option agreement for greater Chinese rights 

VIEW CASE STUDY >>

CLIENT: Xyphos

PARTNER: Astellas

TRANSACTION: Multi-Track Engagement Leading to Acquisition of Xyphos by Astellas

VIEW CASE STUDY >>

CLIENT: Anokion

PARTNER: Kanyos Bio

TRANSACTION: Rapid M&A Advisory

VIEW CASE STUDY >>

CLIENT: Chimerix

PARTNER: SymBio Pharmaceuticals Limited

TRANSACTION: Exclusive global licensing agreement with SymBio Pharmaceuticals for Brincidofovir

VIEW CASE STUDY >>

CLIENT: Pipeline Therapeutics

PARTNER: Sirocco Therapeutics

TRANSACTION: Rapid M&A advisory

VIEW CASE STUDY>>

 

 

CLIENT: Mesa Biotech

TRANSACTION:

Growth capital for point-of-care diagnostic product company

$20M Private Placement

 

CLIENT: Rapid Micro Biosystems

TRANSACTION:

Growth capital for automated, rapid microbial detection system for the healthcare product manufacturing sector

VIEW CASE STUDY >>

CLIENT: Pernix Therapeutics

PARTNER: Orexigen Therapeutics

TRANSACTION: Advisor to Pernix in its acquisition of Orexigen Therapeutics for $73.5M

CLIENT: Flora Bioscience

PARTNER: Olm Diagnostics

TRANSACTION: Led sell-side partnering process for a women’s health infectious disease POC diagnostic

VIEW CASE STUDY>>

CLIENT: HCRP

PARTNER: Albireo 

TRANSACTION: Advised on commercial potential of elobixibat in Japan

CASE STUDY>>

CLIENT: Corsair Pharma

PARTNER: United Therapeutics

TRANSACTION: Exclusive IP licensing agreement 

VIEW CASE STUDY >>

 

CLIENT: Histogenics

PARTNER: MEDINET 

TRANSACTION: Sell-Side process for NeoCart® leading to a Japan licensing agreement with MEDINET ​

VIEW CASE STUDY>>

 

CLIENT: Regeneron

PARTNER: Asahi Kasei Pharma

TRANSACTION: Facilitated negotiations between the US and Japan leading to the partnering in Japan of Sarilumab 

 

 

 

CLIENT: TesoRx 

PARTNER: ASKA 

TRANSACTION: Advised on expansion of existing collaboration on TSX-011 in addition to ASKA equity investment in TesoRx

CLIENT: Spero Therapeutics

PARTNER: Meiji Seika Pharma Co.,Ltd

TRANSACTION: Advised on Japan buy-side process leading to exclusive License Agreement for Meiji’s carbapenem, SPR-994

CLIENT: Veloce BioPharma 

PARTNER: Maruho

TRANSACTION: Assisted partnership with Maruho including an equity investment from Maruho into Veloce

VIEW CASE STUDY>> 

CLIENT: Innocoll

PARTNER: Gurnet Point Capital

TRANSACTION: Advised on company acquisition

CASE STUDY >>

CLIENT: Pieris

PARTNER: Servier

TRANSACTION:
Global Multi-Program Immuno-Oncology Alliance

 

VIEW CASE STUDY>>

CLIENT: Pieris

PARTNER: ASKA Pharmaceutical

TRANSACTION:
Sell-side Japan/Asia collaboration PRS-080

 

 

VIEW CASE STUDY>>

tesorx-aska

CLIENT: TesoRX

PARTNER: ASKA Pharmaceutical

TRANSACTION:
Sell-side Japan licensing agreement for THG-1001

VIEW CASE STUDY >>

 

 

cymabay-kowa

CLIENT: CymaBay Therapeutics

PARTNER: Kowa

TRANSACTION:
Sell-Side Process Leading to US licensing agreement for arhalofenate

VIEW CASE STUDY »

strongbridge-taro

CLIENT: Strongbridge Biopharma

PARTNER: TaroPharma

TRANSACTION:
Buy-side US rights acquisition for Keveyis

VIEW CASE STUDY>>

 

CLIENT: Thar Pharmaceuticals

TRANSACTION:
Multi-Track Sell-Side and Financing Engagement Leading to Acquisition

 

 

VIEW CASE STUDY »

 

CLIENT: NeoTX Therapeutics

PARTNER: Active Biotech

TRANSACTION:
Buy-side licensing agreement for ANYARA

savara-serendex

CLIENT: Savara

PARTNER: Serendex Pharmaceutical

TRANSACTION:
Identified and Initiated buy-side acquisition

VIEW CASE STUDY>>

CLIENT: Strategic Science & Technologies, LLC

TRANSACTION:
Sell-side license for Canadian rights of IbuCream

CLIENT: Advaxis Immunotherapies

TRANSACTION:
Immuno- Oncology Advisor

MedgenicsKHK

CLIENT: Medgenics, Inc.

PARTNER: Kyowa Hakko Kirin

TRANSACTION:
Leveraging relationships in Japan to facilitate collaboration to develop and commercialize KHK’s anti-LIGHT mAb.

VIEW CASE STUDY>>

CLIENT: Strongbridge Biopharma

TRANSACTION:
Raised $25M in a U.S. initial public offering issuing 2,500,000 shares at $10 per share

View case study »

logos

CLIENT: Regeneron

PARTNER: Mitsubishi Tanabe Pharma

TRANSACTION:
Facilitating negotiations between US and Japan to speed deal execution.

View case study »

Logos

CLIENT: Armetheon

PARTNER: Lees Pharma

TRANSACTION:
Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand

View case study »

CLIENT: Strongbridge Biopharma

PARTNER: Antisense Therapeutics

TRANSACTION:
Buy-side licensing agreement for ALT1103 for Acromegaly

CLIENT: Strongbridge Biopharma

PARTNER: Aspireo Pharmaceuticals

TRANSACTION:
Buy-side product acquisition of Somatoprim for Acromegaly

CLIENT: Strongbridge Biopharma

PARTNER: Investors

TRANSACTION:
Private Placement of $33.2M

Locust_Onxeo_DaraBiosciences

CLIENT: Onxeo

PARTNER: Dara BioSciences

TRANSACTION:
Commercialization agreement for North American rights to Oravig

View case study »

Locust_Armetheon

CLIENT: Armetheon

PARTNER: Investors

TRANSACTION:
Series B Financing of $24M

View press release »

Stonebridge_Logo_Website

CLIENT: Strongbridge
Biopharma

PARTNER: Investors

TRANSACTION:
Private Placement of $26.4M

View press release »

Locust_Strategic

CLIENT: Strategic Science & Technologies, LLC

PARTNER: Global OTC Player

TRANSACTION:
US Option Agreement for IbuCream (topical ibuprofen)

View case study »

Locust_Teso_Aspen

CLIENT: TesoRx

PARTNER: Aspen

TRANSACTION:
Regional License Agreement and Investment for an Oral Unmodified Testosterone Replacement.

View case study »

Locust_Fabrus_Senesco

CLIENT: Fabrus

PARTNER: Senesco

TRANSACTION:
Merger between Fabrus and Senesco Technologies

View case study »

Locust_Armetheon

CLIENT: Armetheon

PARTNER: Investors

TRANSACTION:
Series A Financing of $7M

View press release »

Locust_Bioalliance_Innocutis

CLIENT: BioAlliance Pharma

PARTNER: Innocutis

TRANSACTION:
US Commercialization Agreement for Sitavig® (acyclovir mucoadhesive tablet)

View case study »

Locust_Otsuka_Proteus

CLIENT: Otsuka

PARTNER: Proteus

TRANSACTION:
$62.5 Million Follow on Financing

View case study »

Locust_Otsuka_Proteus

CLIENT: Otsuka

PARTNER: Proteus

TRANSACTION:
Worldwide License and Collaboration Agreement

View case study »

Locust_Intermune_Vidara

CLIENT: InterMune

PARTNER: Vidara

TRANSACTION:
Actimmune Product Divestiture for $55M upfront plus 2 year royalty

View case study »

Locust_Otsuka_Lundbeck

CLIENT: Otsuka

PARTNER: Lundbeck

TRANSACTION:
Worldwide Co-Pro, Co-Dev Agreement for Abilify Depotand OPC-34712

View case study »

Locust_Ascenta_Debiopharm

CLIENT: Ascenta

PARTNER: Debiopharm Group

TRANSACTION:
Worldwide Licensing Agreement for AT-406

View case study »

Locust_Angio_Geron

CLIENT: Angiochem

PARTNER: Geron

TRANSACTION:
Worldwide Licensing Agreement for ANG1005 and Research Collaboration for Telomerase

View case study »

Locust_Synthetic_Novartis

CLIENT: Synthetic Genomics

PARTNER: Novartis

TRANSACTION:
Advisor in Forming New Company Synthetic Genomics Vaccines Inc. and Advisor on Structuring

View case study »

Locust_Strategic

CLIENT: Strategic Science & Technologies, LLC

PARTNER: Undisclosed

TRANSACTION:
Worldwide Licensing Agreement for IbuCream (topical ibuprofen)

View case study »

Locust_Concordian_Ono

CLIENT: Concordia Pharmaceuticals

PARTNER: Ono

TRANSACTION:
Licensing Agreement for Salirasib in Japan

View case study »